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The invasion of erythrocytes by Plasmodium falciparum occurs through multiple pathways that can be studied
in vitro by examining the invasion of erythrocytes treated with enzymes such as neuraminidase, trypsin, and
chymotrypsin. We have studied the invasion pathways used by 31 Kenyan P. falciparum isolates from children
with uncomplicated or severe malaria. Six distinct invasion profiles were detected, out of eight possible profiles.
The majority of isolates (23 of 31) showed neuraminidase-resistant, trypsin-sensitive invasion, characteristic
of the pathway mediated by an unknown parasite ligand and erythrocyte receptor “X.” The neuraminidase-
sensitive, trypsin-sensitive phenotype consistent with invasion mediated by the binding of parasite ligand
erythrocyte binding antigen 175 to glycophorin A, the most common invasion profile in a previous study of
Gambian field isolates, was seen in only 3 of 31 Kenyan isolates. No particular invasion profile was associated
with severe P. falciparum malaria, and there was no significant difference in the levels of inhibition by the
various enzyme treatments between isolates from children with severe malaria and those from children with
uncomplicated malaria (P, >0.1 for all enzymes; Mann-Whitney U test). These results do not support the
hypothesis that differences in invasion phenotypes play an important role in malaria virulence and indicate
that considerable gaps remain in our knowledge of the molecular basis of invasion pathways in natural P.
falciparum infections.
Erythrocyte invasion by merozoites is a crucial step during
the intraerythrocytic asexual cycle of Plasmodium falciparum.
This stage of the parasite infection causes an estimated 500
million clinical malaria cases per year (29), and understanding
the parasite’s biology is important for the identification of new
drugs and vaccines. Four key stages of invasion have been
described: merozoite attachment to the erythrocyte, apical re-
orientation, tight-junction formation, and finally, erythrocyte
entry that involves the formation of a parasitophorous vacuole
(8). The molecular basis of these processes is not fully under-
stood; however, several parasite molecules involved in invasion
have been identified and are encoded by two families of genes:
erythrocyte binding antigens (EBA-175, EBA-140, and EBA-
181) and reticulocyte binding protein homologues (Rh1, Rh2a,
Rh2b, and Rh4) (8). It is now clear that in contrast to P. vivax
(which requires the Duffy antigen receptor), P. falciparum
merozoites interact with multiple alternative receptors that are
important for erythrocyte invasion (8). Invasion pathways have
been identified by examining the entry of merozoites into
erythrocytes that have mutant or null receptor phenotypes (11,
22) and by removing erythrocyte surface receptors with enzyme
treatments (2, 6, 19), the commonly used enzymes being neur-
aminidase, trypsin, and chymotrypsin. Neuraminidase removes
sialic acids from the erythrocyte surface. Testing the ability of
a parasite isolate to invade neuraminidase-treated erythrocytes
defines whether the isolate is sialic acid dependent or indepen-
dent. Trypsin removes surface glycoproteins, including glyco-
phorin A (GPA) and glycophorin C (GPC). Chymotrypsin has
a different specificity from trypsin and removes other proteins,
including glycophorin B (GPB) and Band 3.
The invasion profiles of various P. falciparum laboratory
strains have been defined previously by studying the invasion of
enzyme-treated erythrocytes. Presently, six different invasion
profiles of laboratory strains have been described, as shown in
Table 1. It has been found that the pathways described for
particular laboratory strains are consistent across laboratories,
indicating that the invasion phenotype is stable (2, 6), with an
exception being a report showing different invasion profiles for
two 3D7 lines (4).
Following from the work on laboratory strains, there has
been recent interest in studying the invasion phenotypes of
field isolates to understand the erythrocyte invasion process in
natural P. falciparum infections. This issue is of particular
relevance for the design of vaccines against blood-stage anti-
gens, which may target specific invasion pathways. To date,
there have been three studies of the invasion profiles of field
isolates, with isolates collected in India, The Gambia, and
Brazil (1, 15, 21). These studies have reported the invasion
profiles of field isolates invading neuraminidase- or trypsin-
treated erythrocytes (1, 21) or neuraminidase-, trypsin-, or
chymotrypsin-treated erythrocytes (15). Among isolates from
each study site, several distinct invasion profiles were detected,
although there was one preferred invasion profile employed by
the majority of isolates from each site. Twelve out of 15 Indian
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isolates used a neuraminidase- and trypsin-resistant pathway
(21), whereas among isolates from The Gambia and Brazil, the
neuraminidase- and trypsin-sensitive invasion profile was pre-
dominant (30 of 38 isolates in The Gambia and 7 of 14 isolates
in Brazil) (1, 15). The study in The Gambia indicated that the
majority of isolates probably invaded through the EBA-175/
GPA pathway (or the EBA-140/GPC pathway, as the GPC
receptor is also neuraminidase and trypsin sensitive) (1), but
the Brazilian study showed that 5 of the 7 Brazilian isolates
with this enzyme sensitivity receptor phenotype could invade
erythrocytes which lacked GPA (15). In addition, approxi-
mately a third (5 of 14) of the Brazilian isolates used trypsin-
resistant receptors, which is an unusual phenotype elsewhere
(15).
All of the above-cited studies were based on field isolates
collected from patients with uncomplicated malaria (1, 15, 21).
Parasite isolates from patients with severe P. falciparum ma-
laria have not been studied previously, and it is unknown
whether isolates from patients with severe malaria may use a
specific invasion pathway or possibly a larger range of invasion
pathways than isolates from patients with mild malaria. We
therefore investigated the invasion profiles of Kenyan field
isolates collected from children diagnosed with either uncom-
plicated or severe P. falciparum malaria and tested for an
association between the invasion profile and disease severity.
MATERIALS AND METHODS
Parasite isolates. Parasite isolates were collected from patients with P. falcip-
arum infections attending Kilifi District Hospital, Kilifi, Kenya, from December
2003 to January 2004 and June to August 2004. At this site, malaria transmission
is seasonal (June to August and December to February), with the average
number of infective bites per individual estimated at approximately 10 to 30 per
year (13). Children with cerebral malaria (those that could not be roused from a
comatose state with a Blantyre score of 2), prostration (the inability to sit or,
for babies, to breast feed), or respiratory distress (abnormally deep breathing)
were considered to have severe malaria. This clinical definition identifies ap-
proximately the same group of children at risk for life-threatening malaria as the
more comprehensive World Health Organization criteria (17). Uncomplicated
cases of malaria were defined as those in children presenting at the outpatient
department of the same hospital with no signs of severe disease who were treated
successfully with oral antimalarial therapy. Blood samples were collected imme-
diately prior to treatment after obtaining informed consent from the children’s
parents or guardians, and protocols were approved by ethical review boards in
the United Kingdom and Kenya. The isolates were collected into heparinized
tubes and processed within 12 h of collection. Lymphocytes and the buffy coat
were removed, and the erythrocytes were washed three times in incomplete
RPMI 1640 medium (incRPMI; RPMI 1640 medium plus 25 mM HEPES, 2 mM
glutamine, 25 mM glucose, and 25 g of gentamicin/ml, pH 7.2 to 7.4). The
parasites were cultured as described below.
Parasite genotyping. For DNA analysis, approximately 200 l of each parasite
culture (equivalent to 5 l of packed erythrocytes) was sampled before growth
and DNA was extracted by using the QIAamp DNA blood mini kit (QIAGEN,
United Kingdom). To test for the presence of multiple clones of P. falciparum
among the isolates, the highly polymorphic repeat sequences in two loci (msp1
block 2 and msp2 block 3) were amplified by using a nested PCR method with
allele type-specific internal primers (28).
SI. The selectivity index (SI) is a measure of whether invasion is a random
process or whether more multiple invasions occur than would be expected if
invasion proceeded by chance alone. An increase in the number of multiple
invasions is thought to occur when only a subset of the total red blood cell (RBC)
population is available for invasion (27). An SI of 1 indicates the random
invasion of RBCs, whereas an SI of, for example, 2 indicates twofold more
multiply infected RBCs than would be expected if invasion occurred by chance
alone. To assess the SI, thin smears from the blood sample collected from each
patient were prepared and stained with Giemsa. Three hundred ring-infected
erythrocytes per slide were counted, and the number of rings in each erythrocyte
was recorded. The SI was calculated as described in detail previously (27).
Briefly, the number of observed multiply infected erythrocytes (i.e., those with
two or more rings per erythrocyte) was divided by the number of expected
multiply infected erythrocytes. The latter was calculated according to a Poisson
distribution, where lambda (the mean number of parasites per erythrocyte) is
ln(1  the level of parasitemia). The level of parasitemia was calculated as the
number of infected erythrocytes per 1,000 examined.
Parasite cultures. Field isolates were cultured in complete RPMI 1640 me-
dium (incRPMI plus 10% pooled human AB serum). Cultures were set up at a
hematocrit value of 1 to 2% with blood group O erythrocytes and incubated at
37°C with 3% CO2, 1% O2, and 96% N2. Cultures were monitored for 18 to 36 h
by using Giemsa smears, and only those isolates with normal morphology that
matured to the schizont (segmenter) stage were included in the study. Two
laboratory strains, P. falciparum clone 7G8 (11) and strain Dd2 (6), were studied
as controls for the invasion inhibition assays. The laboratory strains were cul-
tured in complete RPMI 1640 medium as described above except with 10%
pooled human O serum. Laboratory strains were synchronized by sorbitol lysis
(14).
Donor erythrocytes. Donor erythrocytes for the field isolate invasion assays
were collected from a single Caucasian donor (blood group O). Ten milliliters
of whole blood was collected into 2 ml of acid citrate dextrose, mixed to prevent
coagulation, and stored at 4°C for a maximum of 2 weeks. Before use, the white
blood cells were removed by layering 6 ml of whole blood over 5 ml of Lym-
phoprep (Axis Shield) and centrifuging for 20 min at 400  g. The erythrocyte
pellet was washed twice with 10 ml of incRPMI, resuspended at a 50% hemat-
ocrit value, and used within 1 week. O erythrocytes for experiments with
laboratory strains were obtained from the Scottish Blood Transfusion Service.
They were treated as described above.
Enzyme treatment of erythrocytes. Frozen aliquots of trypsin, chymotrypsin,
and the soybean trypsin inhibitor were prepared. The enzymes were dissolved in
incRPMI to the required concentrations, as follows: trypsin, 1 mg/ml; chymo-
trypsin, 1 mg/ml; and soybean trypsin inhibitor, 0.5 mg/ml. They were then frozen
in 1-ml aliquots at 20°C. The neuraminidase (Vibrio cholerae neuraminidase;
Calbiochem) was reconstituted in distilled H2O and stored at 4°C according to
the manufacturer’s instructions. The enzyme treatment was based on protocols
described previously (1). An aliquot of each of the required enzymes was thawed.
A tube with 50 mU of neuraminidase in 1 ml of incRPMI was prepared, and one
control tube with 1 ml of incRPMI was prepared. To each tube containing 1 ml
of an enzyme mixture (neuraminidase, chymotrypsin, or trypsin) or incRPMI
alone (control), a volume of 100 l of packed donor erythrocytes was added. The
tubes were incubated on a rotating wheel for 1 h at 37°C. After that time, all
samples were washed once with 1 ml of incRPMI and then soybean trypsin
inhibitor was added to the trypsin and chymotrypsin samples to inhibit the
enzymes. IncRPMI was added to the control and neuraminidase samples. The
samples were incubated on a rotating wheel for 10 min at room temperature and
then washed three times before the erythrocytes were resuspended at a 50%
hematocrit value in incRPMI. The enzyme-treated erythrocytes and controls
were stored at 4°C and used for a maximum of 1 week, after which samples were
freshly prepared.
Agglutination of enzyme-treated erythrocytes. Agglutination assays of enzyme-
treated erythrocytes were carried out to ensure that the specific epitopes were
being removed successfully. A 20-l sample of each of the different erythrocyte
suspensions was diluted in 200 l of 0.9% NaCl. Forty microliters of a 5%
hematocrit sample of each aliquot was added to the same volume of anti-M
TABLE 1. Invasion profiles of P. falciparum laboratory strains
Invasion profilea Parasite ligandb RBC receptor Reference(s)
NmS TS CTR EBA-175 GPA 22, 26
BAEBL/EBA-140 GPC 16, 18
NmS TR CTS ? GPB 6
JESEBL/EBA-181 Receptor E 9
NmS TR CTR PfRh1 Receptor Y 23, 31
NmR TS CT? ? Receptor X 6
NmR TR CTS PfRh2b Receptor Z 7
MSP1 Band 3 10
AMA1 Kx 12
NmR T? CTR PfRh4 ? 30
a Nm, neuraminidase; T, trypsin; CT, chymotrypsin; S, sensitive; R, resistant.
b Pf, P. falciparum.
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antibody (Biotest [UK] Ltd.), anti-S antibody (Biotest [UK] Ltd.), or peanut
(Arachis hypogaea) lectin (Sigma; reconstituted in phosphate-buffered saline and
stored in aliquots at 20°C) in a Pyrex tube. The samples in the tubes were
mixed, and the tubes were covered with Parafilm. The samples were incubated
for 5 min (anti-S antibody) or 30 min (anti-M antibody and peanut lectin) at
room temperature. The anti-S antibody samples were centrifuged for 1 min at
150  g before the agglutination was assessed. To check for agglutination, the
pellets were gently dislodged and the agglutination was assessed by eye and scored
(one large agglutinate, ; small agglutinates, ; and no agglutinates, ). Trypsin
activity was shown by the complete loss of anti-M-mediated agglutination, chymo-
trypsin activity by the complete loss of anti-S-mediated agglutination, and neuramin-
idase activity by the gain of peanut lectin-mediated agglutination after enzyme
treatment.
Invasion assays. The assay to determine the parasite multiplication rate
(PMR) in the first cycle of in vitro culture was set up as described previously (3,
5). Invasion inhibition assays were carried out with two laboratory strains (7G8
and Dd2) in three independent experiments and with the Kenyan field isolates in
a single experiment. All parasites were cultured as described above until the
mature schizont stage. The schizont samples were enriched by centrifugation
through 55% Percoll. The schizonts from the enriched samples were washed
twice, and the schizont concentrations were adjusted to around 1% parasitemia
with normal group O RBCs or the matching enzyme-treated RBCs. The mix-
tures were incubated in 96-well plates at a volume of 50 l and a hematocrit
value of 2%, with duplicate wells for each treatment. The 96-well plate was
placed within a gas modulator chamber to allow culturing in 3%CO2, 1% O2, and
96% N2 for 24 h at 37°C. Thin blood films from the preinvasion sample and the
samples of ring-invaded erythrocytes after 24 h were made and stained with
Giemsa to determine the level of parasitemia. At least 1,000 erythrocytes from
each slide of the duplicate wells per sample were counted. The PMR is deter-
mined by dividing the number of ring-infected erythrocytes after invasion by the
preinvasion level of parasitemia. Invasion inhibition was measured as follows:
100  [(PMR after enzyme treatment/control PMR)  100)]. In a few cases, no
ring-infected erythrocytes were seen and the invasion inhibition was measured as
100%. Where the PMR in enzyme-treated erythrocytes was higher than that in
control erythrocytes, the invasion inhibition is given as a negative value due to an
increase in invasion.
Rosette frequency. Mature, pigmented trophozoite-stage parasites were
stained with 25 g of ethidium bromide/ml for 5 min at 37°C, and a wet prep-
aration was assessed for rosetting by microscopy. The rosette frequency is the
percentage of mature infected erythrocytes binding two or more uninfected
erythrocytes.
Statistical analysis. Statview software (version 5; SAS Institute Inc.) was used
for statistical analysis. All statistical tests of the Kenyan field isolate data were
nonparametric tests as the data were not normally distributed. For statistical
analyses, any negative invasion inhibition results were counted as 0. The Mann-
Whitney U test or Kruskal-Wallis test was used to look for differences between
two or more groups, respectively. Correlations between the SI, the PMR, the
rosette frequency, and the invasion inhibition data were determined with Spear-
man’s rank correlation.
RESULTS
Diversity in invasion profiles of Kenyan P. falciparum iso-
lates. The invasion profiles of 31 Kenyan field isolates in the
first cycle of in vitro growth were examined. These isolates
were a subset of those studied previously to examine the rela-
tionships among the PMR, the erythrocyte SI, and malaria
severity (5). The inhibition of the invasion of neuraminidase-
treated erythrocytes by Kenyan field isolates varied from
32.4% (indicating an increase in invasion) to 100% (i.e., no
ring-infected erythrocytes were counted), with a median of
12.8%. The inhibition of the invasion of trypsin-treated eryth-
rocytes varied from 28 to 100%, with a median of 89.1%. The
inhibition of the invasion of chymotrypsin-treated erythrocytes
ranged from 66.7 to 100%, with a median of 62.8%.
The invasion profiles of the field isolates were defined by the
sensitivity of the isolates to invasion inhibition by neuramini-
dase, trypsin, and chymotrypsin. Isolates exhibiting levels of
inhibition above 50% compared to the control (no enzyme
treatment) were defined as sensitive, and those with levels
below 50% were defined as resistant according to the common
definition criteria (1, 15). The Kenyan isolates showed six out
of a possible eight invasion profiles (Table 2). The most com-
mon profile, seen in 18 of 31 isolates, was neuraminidase-
resistant and trypsin- and chymotrypsin-sensitive invasion,
which matches the profile of the laboratory strain 7G8 (Table
2) (6). Five of the Kenyan isolates also showed neuraminidase
resistance and trypsin sensitivity but were chymotrypsin resis-
tant. Three of the Kenyan isolates were sensitive to all three
enzymes, indicating a pathway whose molecular basis is com-
pletely unknown and that has been identified previously in only
one Brazilian field isolate (15). Three of the isolates showed no
sensitivity to chymotrypsin and were neuraminidase and tryp-
sin sensitive, exhibiting the invasion profile predominant
among samples of Brazilian isolates and Gambian isolates (al-
though the chymotrypsin sensitivity of the Gambian isolates is
unknown) (1, 15). One isolate showed the same profile as the
laboratory strain Dd2 (6) and was neuraminidase sensitive and
chymotrypsin and trypsin resistant. Finally, one isolate was
resistant to both neuraminidase and trypsin treatment but was
sensitive to chymotrypsin treatment. Two more profiles are
theoretically possible but were not seen in this study (resis-
tance to all three enzymes and a neuraminidase-sensitive, tryp-
sin-resistant, and chymotrypsin-sensitive profile).
The minimum number of parasite genotypes per isolate
from each patient was estimated for isolates from 12 patients,
and as expected for an area with moderately high levels of
malaria transmission, multiple infections were common (mean
number of genotypes overall, 2.2; mean number of genotypes
in isolates from patients with severe malaria [n  6], 1.5; and
mean number of genotypes in isolates from patients with un-
complicated malaria [n  6], 2.8). Four of six patients with
severe malaria had single infections, whereas none of the pa-
tients with uncomplicated malaria had single infections. The
presence of multiple genotypes within an isolate from a single
patient has the potential to complicate the interpretation of
invasion profile data, because the profile seen may be a com-
posite of different parasite types. In a mixed-clone infection, it
is unclear whether a single genotype tends to dominate the
infection or whether the isolate consists of roughly equal pro-
portions of the different clones. A previous study found no
significant difference in the invasion profiles corresponding to
single-clone infections and multiple-clone infections, suggest-
ing that the presence of mixed-clone infections does not nec-
essarily confound the data (1). In addition, for practical rea-
sons, the examination of only single-clone infections in areas
with moderate to high levels of transmission would severely
restrict the number of samples available and would exclude
potentially important data.
Invasion profiles of Kenyan isolates and malaria severity.
Previous studies of the invasion pathways used by field isolates
have been carried out with isolates taken from patients with
uncomplicated malaria. It is unknown whether isolates from
patients with severe P. falciparum malaria may invade by a
specific invasion pathway. We therefore compared the levels of
inhibition of the invasion of enzyme-treated erythrocytes by
isolates collected from patients with severe and uncomplicated
malaria. Nineteen of the isolates were from children with un-
complicated malaria (mean age, 46.3 months [standard devia-
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tion, 34.9 months]; mean hemoglobin level, 9.8 g/dl [standard
deviation, 1.3 g/dl[), and 12 isolates were collected from chil-
dren with severe malaria (mean age, 19.6 months [standard
deviation, 11.2 months]; mean hemoglobin level, 7.7 g/dl [stan-
dard deviation, 3.1 g/dl]). Of the patients with severe malaria,
three had cerebral malaria, four showed prostration and respi-
ratory distress, one had respiratory distress only, one exhibited
prostration and severe anemia, and three presented with pros-
tration only. As seen in Table 2, the isolates from both clinical
groups showed similar distributions of recorded invasion pro-
files. Figure 1 shows the median levels of the inhibition of
invasion by isolates from patients with uncomplicated or severe
malaria in association with each of the enzyme treatments,
compared to the invasion of non-enzyme-treated control eryth-
rocytes. The levels of inhibition did not differ between the
isolates from patients with uncomplicated malaria and those
from patients with severe malaria in association with any of the
enzyme treatments (P, 0.1 for all enzyme treatments; Mann-
Whitney U test).
Invasion profiles and other parasite variables. We deter-
mined the SIs (a measure of whether invasion occurs randomly
in any available erythrocyte or is selective for a subset of
erythrocytes) (27), PMRs (5), and rosette frequencies (a par-
asite virulence-associated factor) (24, 25) for the isolates in-
cluded in this study as part of a larger study of PMRs and
clinical malaria isolate phenotypes described elsewhere (5).
None of these variables correlated significantly with the level
of inhibition by any of the enzyme treatments (P  0.1; Spear-
man’s rank correlation).
ABO blood group and invasion phenotype. We found a
significant difference in neuraminidase sensitivity among iso-
lates taken from patients of different ABO blood group types
TABLE 2. Invasion profiles of Kenyan field isolates
Invasion profilea Isolateb Symptoms ofclinical severityc
% Inhibition byd:
PMRe SIe ABO bloodgroup typefNeuraminidase
(50 mU/ml)
Trypsin
(1 mg/ml)
Chymotrypsin
(1 mg/ml)
NmRTSCTS 7G8 33.3 (19.2) 80.7 (5.5) 58.2 (7.5)
6 U NA 9.3 86.1 62.8 2.91 2.35 O
7 U NA 12.8 83.0 76.6 4.70 1.28 A
8 S Pr, RD, An 7.1 78.6 78.6 1.75 2.54 A
9 S C 32.4 97.2 90.1 2.73 1.85 O
10 S Pr, RD 0 87.8 73.2 2.05 2.06 A
11 U NA 49.1 75.4 59.7 2.64 1.55 O
12 S Pr, RD 22.8 85.7 62.9 2.50 1.96 O
13 U NA 8.5 95.8 56.3 5.92 0.37 O
14 U NA 1.1 89.1 56.5 3.29 1.32 O
15 U NA 12.5 79.2 58.3 4.00 ND O
16 S C, RD 0 92.9 92.9 3.50 1.57 O
17 U NA 7.5 79.1 64.2 6.09 0 O
18 U NA 42.0 88.0 94.0 4.17 1.91 O
19 U NA 17.0 85.1 59.6 1.74 4.97 O
20 U NA 10.3 92.3 92.3 2.29 1.13 O
21 S Pr 23.5 94.1 70.6 0.71 1.31 B
22 S Pr, RD, An 33.3 92.6 55.6 1.13 2.33 B
23 U NA 29.6 77.8 77.8 1.50 3.74 O
NmRTSCTR 1 U NA 13.8 100 43.1 0.58 2.34 O
2 U NA 8.9 91.1 48.2 3.15 1.76 ND
3 S RD 13.2 89.5 42.1 1.58 1.71 O
4 S C, RD 6.3 100 66.7 0.48 1.89 A
5 U NA 23.6 94.4 28.3 2.33 1.31 O
NmSTSCTS 29 S Pr, An 100 82.5 90.2 1.43 2.45 B
30 U NA 56.0 100 100 0.69 ND A
31 U NA 56.1 100 63.4 0.82 1.51 B
NmSTSCTR 26 S Pr 75.2 96.0 30.2 3.51 1.63 O
27 U NA 100 100 31.5 0.73 2.35 AB
28 U NA 58.0 81.3 38.6 1.76 0.86 B
NmSTRCTR Dd2 89.2 (10.2) 47.6 (16.9) 11.1 (30.5)
25 U NA 58.5 28.6 8.3 2.17 3.27 ND
NmR TR CTS 24 S Pr 16.0 28.0 100 0.25 1.76 B
a Nm, neuraminidase; T, trypsin; CT, chymotrypsin; S, sensitive; R, resistant.
b Each field isolate designation includes a label to indicate whether the isolate was derived from a child with uncomplicated (U) or severe (S) malaria. Laboratory
strains 7G8 and Dd2 are indicated in italics. For the laboratory strains, the means (and standard deviations) of results from three experiments are shown. Field isolate
data are from a single experiment for each isolate. Field isolates corresponding to infections with the indicated number of genotypes are as follows: one genotype,
isolates 8, 21, 22, and 26; two genotypes, isolates 2, 11, 12, and 13; three genotypes, isolates 9 and 23; four genotypes, isolates 5 and 14. Other isolates were not
genotyped.
c Severe malaria was indicated by a comatose state (C), respiratory distress (RD), prostration (Pr), and anemia (An). For the uncomplicated malaria cases, NA
indicates not applicable.
d Percentages of inhibition of invasion are relative to the level of invasion of non-enzyme-treated control erythrocytes. A result of 100% inhibition indicates that no
rings of infected erythrocytes were counted, whereas a negative percentage of inhibition (e.g., 32%) indicates an increase in invasion compared to the control.
e These results have been published previously in more detail (5). PMR, parasite multiplication rate; SI, selectivity index.
f For two samples, the corresponding ABO type was not determined (ND).
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(Fig. 2). Seventeen isolates were collected from patients with
blood group O, six were from patients with blood group B, and
five were from patients with blood group A. The single sample
from a patient with blood group AB was excluded from this
analysis, and for two samples the corresponding blood group
data were missing. It was found that isolates from patients with
blood group B were more inhibited by the neuraminidase
treatment of erythrocytes, with a median level of inhibition of
44.7% (interquartile range [IQR], 23.5 to 58.0%; n  6) com-
pared to 7.1% (IQR, 3.1 to 34.4%; n 5) and 9.3% (IQR, 0 to
23.3%; n  17) for blood groups A and O, respectively (P 
0.02; Kruskal-Wallis test). This finding indicates that isolates
growing in blood group type B are more dependent on sialic
acid for the invasion of type O erythrocytes (the donor of the
erythrocytes used for all invasion assays was type O). Trypsin
or chymotrypsin sensitivity was not related to the ABO blood
group. No other patient variable (age, level of parasitemia,
hemoglobin level, or white blood cell count) was associated
with the level of inhibition of the invasion of enzyme-treated
erythrocytes.
DISCUSSION
We examined the abilities of Kenyan field isolates to invade
erythrocytes treated with three different enzymes in order to
assess the invasion pathways used by parasites isolated from
patients with clinical P. falciparum malaria infections. In con-
trast to the results of previous studies from The Gambia and
Brazil (1, 15), but similar to those of a study from India (21),
it was found that the neuraminidase- and trypsin-sensitive,
chymotrypsin-resistant receptors (characteristic of EBA-175/
GPA- and EBA-140/GPC-mediated invasion) were rarely used
by Kenyan field isolates (Table 2). Geographical variation in
invasion profiles may have important implications for blood-
stage vaccines which target antigens involved in invasion path-
ways. For example, a vaccine based on EBA-175 and/or EBA-
140 may not be as effective in Kenya as it would be in The
Gambia. Furthermore, the redundancy of invasion pathways
used by field isolates indicates that a vaccine based on only one
invasion ligand may not greatly inhibit P. falciparum invasion
and growth but may instead select for parasites which invade
by different mechanisms.
The invasion patterns of the majority of the Kenyan isolates
(23 of 31) could be broadly described as neuraminidase resis-
tant and trypsin sensitive. This profile was originally described
for the laboratory strain 7G8, and it was inferred that this
profile indicated the existence of an erythrocyte receptor “X”
(6, 11). The finding that this pathway occurs commonly in
clinical malaria isolates in Kenya argues that further research
to delineate the molecular interactions underlying this pathway
is of major importance. Indeed, it is likely that X is not only
one receptor, as invasion by this pathway may be either sensi-
tive or resistant to the treatment of erythrocytes with chymo-
trypsin. The parasite ligand(s) involved in the neuraminidase-
resistant, trypsin-sensitive pathway is also unclear, although
one possible candidate is the Rh4 protein that mediates neura-
minidase-resistant, chymotrypsin-resistant invasion (30) (the
trypsin sensitivity of Rh4-mediated invasion has not yet been
described).
The work described here constitutes the first study to exam-
ine the invasion profiles of field isolates collected from chil-
dren with severe P. falciparum malaria. Although no significant
association between the invasion profiles and disease severity
was seen in this study, the sample size was small (only 12
isolates were from children with assorted severe malaria syn-
dromes), so we cannot rule out that a difference may be seen
in a larger study, and further work is required. However, the
lack of an observed association between invasion profiles and
disease severity is consistent with the findings of a previous
study of a larger group of isolates collected at the same study
site. No significant differences in the multiplication rates or the
red cell SIs between isolates from children with uncomplicated
malaria and those with severe malaria were observed (5), in
contrast with previous results from Thailand (3). Due to the
FIG. 1. Percentages of inhibition of erythrocyte invasion by Kenyan
field isolates from children with uncomplicated (black bars) or severe
(gray bars) P. falciparum malaria. The erythrocytes were treated with
neuraminidase (Nm; 50 mU/ml), trypsin (T; 1 mg/ml), or chymotrypsin
(CT; 1 mg/ml). The median values are shown; error bars represent
third quartile values. No significant differences between the isolates
from patients with uncomplicated malaria and those from patients with
severe malaria were associated with any of the enzyme treatments
(P, 0.1 for all enzyme treatments; Mann-Whitney U test).
FIG. 2. Percentages of inhibition of the invasion of neuraminidase-
treated erythrocytes by Kenyan field isolates from children with the
ABO blood group A (n  5), B (n  6), or O (n  17). The median
levels of inhibition are shown; error bars represent third quartile val-
ues. Isolates from patients with blood group B were more inhibited by
the treatment of erythrocytes with neuraminidase than those from
patients with blood group A or O (P  0.02; Kruskal-Wallis test).
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strong association between the PMR and disease severity in
Thailand, a study of the invasion profiles of Thai field isolates,
examining whether the high multiplication rates displayed by
isolates from patients with severe malaria can be associated
with overall less sensitivity to the enzyme treatment of eryth-
rocytes or with a specific preferred invasion profile, may pro-
vide further insight.
As knowledge of the P. falciparum ligands involved in inva-
sion increases and technological advances allow their study in
field samples, it is important to characterize the expression
levels of putative ligands and correlate these findings with
invasion phenotypes. Thirteen of the samples analyzed in this
study were also included in a recent study of the expression
profiles of four Rh genes (those encoding Rh1, Rh2a, Rh2b,
and Rh4) and the EBA-175 gene (20). Although the numbers
are small and, therefore, this analysis should be regarded as
preliminary, a positive correlation between the relative levels
of EBA-175 and sensitivity to the treatment of erythrocytes
with neuraminidase was found, consistent with the known
neuraminidase sensitivity of the EBA-175 receptor GPA (26).
One unexpected finding from this study was a significant
difference in the levels of inhibition by neuraminidase treat-
ment depending on the ABO blood group of the host from
which the parasites were isolated. Isolates from patients with
blood group B were the most inhibited by the treatment of
erythrocytes with neuraminidase compared to isolates from
patients with blood group A or O (Fig. 2) (P  0.02; Kruskal-
Wallis test). This finding suggests that the host ABO type may
influence the invasion phenotype of the parasite. It remains
unclear whether these results occurred by chance, as the sam-
ple size was small and the study was not designed to look at the
invasion inhibition in relation to the host ABO blood group
type, but these findings may merit further investigation.
In summary, this work shows that a variety of invasion path-
ways are used by Kenyan field isolates and that there is no
single discernible pathway specifically associated with severe P.
falciparum malaria. Further studies in a variety of geographical
areas with isolates associated with various disease syndromes,
along with parallel studies examining the transcription of par-
asite invasion ligands (20), will be required to fully characterize
the diversity in invasion pathways and indicate if these path-
ways may be effectively targeted by vaccines based on the
relevant ligands.
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